


## Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. **(Currently Amended)** An imidazotriazinone compound represented by the following formula (IA) ~~or (IB)~~:



wherein

A is N or CR<sup>4</sup>;

B is N or CH;

R<sup>1</sup> is substituted or unsubstituted cycloalkyl group or tert-butyl group;

R<sup>2</sup> is a hydrogen atom or C<sub>1</sub>-C<sub>6</sub> alkyl group;

R<sup>3</sup> is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl group; substituted or unsubstituted C<sub>2</sub>-C<sub>6</sub> alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: -NR<sup>5</sup>R<sup>6</sup>, -C(O)R<sup>7</sup>, -SO<sub>2</sub>R<sup>7</sup>, -OR<sup>8</sup>, -NR<sup>8</sup>COR<sup>7</sup>, -NR<sup>8</sup>SO<sub>2</sub>R<sup>7</sup>;

R<sup>4</sup> is a hydrogen atom or C<sub>1</sub>-C<sub>3</sub> alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);

R<sup>5</sup> and R<sup>6</sup> are, same or different from each other, a hydrogen atom; substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl group; substituted or unsubstituted acyl group; or substituted or unsubstituted heterocycloalkyl group;

R<sup>7</sup> is a hydrogen atom; substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl group; substituted or unsubstituted heterocycloalkyl group; OH; -OR<sup>8</sup> or -NR<sup>5</sup>R<sup>6</sup>;

R<sup>8</sup> is a hydrogen atom, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl group; or substituted or unsubstituted heterocycloalkyl group; or pharmaceutically acceptable salts ~~or solvates~~ thereof.

2. **(Canceled)**

3. **(Canceled)**
4. **(Original)** The compound according to claim 1, in which R<sup>1</sup> is substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group.
5. **(Previously Presented)** The compound according to claim 4, in which R<sup>1</sup> is cyclopentyl, cyclohexyl or cycloheptyl.
6. **(Previously Presented)** The compound according to claim 1, in which A is CR<sup>4</sup> wherein R<sup>4</sup> is methoxy or ethoxy group.
7. **(Previously Presented)** The compound according to claim 1, in which B is CH.
8. **(Previously Presented)** The compound according to claim 1, in which R<sup>2</sup> is methyl group.
9. **(Previously Presented)** The compound according to claim 1, in which R<sup>3</sup> is a hydrogen atom; a halogen atom; saturated or unsaturated heterocycloalkyl group; an -NR<sup>5</sup>R<sup>6</sup>, -C(O)R<sup>7</sup>, or -SO<sub>2</sub>R<sup>7</sup> group, wherein R<sup>7</sup> is OH, -OR<sup>8</sup>, -NR<sup>5</sup>R<sup>6</sup> or a substituted or unsubstituted heterocycloalkyl group.
10. **(Currently Amended)** A pharmaceutical composition comprising a compound according to claim 1, or pharmaceutically acceptable salts ~~or solvates~~ thereof as active ingredient.
11. **(Canceled)**